Cargando…

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study

Biologics have transformed management of inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by circulating drug levels has been proposed. We aimed to determine the real-world clinical utility of therapeutic drug monitoring in psoriasis. Within a multicenter (n = 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkinson, Nina, Tsakok, Teresa, Dand, Nick, Bloem, Karien, Duckworth, Michael, Baudry, David, Pushpa-Rajah, Angela, Griffiths, Christopher E.M., Reynolds, Nick J., Barker, Jonathan, Warren, Richard B., Burden, A. David, Rispens, Theo, Stocken, Deborah, Smith, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300405/ https://www.ncbi.nlm.nih.gov/pubmed/30130616 http://dx.doi.org/10.1016/j.jid.2018.07.028

Ejemplares similares

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
por: Pan, Shan, et al.
Publicado: (2020)

Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove
por: Tsakok, Teresa, et al.
Publicado: (2023)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019)

Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
por: Andres-Ejarque, Rosa, et al.
Publicado: (2021)

Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
por: Andres-Ejarque, Rosa, et al.
Publicado: (2021)

Psoriasis and Genetics
por: DAND, Nick, et al.
Publicado: (2020)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Clinical and genetic differences between pustular psoriasis subtypes
por: Twelves, Sophie, et al.
Publicado: (2019)

A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial
por: Cro, Suzie, et al.
Publicado: (2020)

A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial
por: Cornelius, Victoria, et al.
Publicado: (2018)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
por: Warren, R.B., et al.
Publicado: (2018)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Adalimumab for severe psoriasis in Chilean paediatric patients()()
por: Armijo Fernandez, Daniela, et al.
Publicado: (2020)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
por: Yayli, Savas, et al.
Publicado: (2013)

Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Genetic susceptibility to psoriasis: an emerging picture
por: Smith, Rhodri Ll, et al.
Publicado: (2009)

Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis
por: de Natividade, Natallia Barreiros, et al.
Publicado: (2017)

Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial
por: Jacobse, Justin, et al.
Publicado: (2021)

Genetic Validation of Psoriasis Phenotyping in UK Biobank Supports the Utility of Self-Reported Data and Composite Definitions for Large Genetic and Epidemiological Studies
por: Saklatvala, Jake R., et al.
Publicado: (2023)

Psoriasis and other complex trait dermatoses: from loci to functional pathways
por: Capon, Francesca, et al.
Publicado: (2011)

Thalamic stroke in a young adult with severe psoriasis refractory to adalimumab
por: Kadayakkara, Deepak Kana, et al.
Publicado: (2015)

Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence
por: Lombardi, G, et al.
Publicado: (2016)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab
por: Alahmari, Hana S., et al.
Publicado: (2019)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: Panahi, M., et al.
Publicado: (2021)

Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy
por: KOKOLAKIS, Georgios, et al.
Publicado: (2020)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
por: Phan, Duc Binh, et al.
Publicado: (2023)

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
por: Mahil, Satveer K., et al.
Publicado: (2021)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Zenas Z.N., et al.
Publicado: (2018)

‘On the surface’: a qualitative study of GPs’ and patients’ perspectives on psoriasis
por: Nelson, Pauline A, et al.
Publicado: (2013)

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
por: Berends, Sophie E., et al.
Publicado: (2019)

Clinical Disease Measures in Generalized Pustular Psoriasis
por: Burden, A. David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2e4q031ifasfuulvu7a5q1hkst